Celsion Corporation (NASDAQ:CLSN) was upgraded by equities researchers at ValuEngine from a “strong sell” rating to a “sell” rating in a report issued on Friday.

Several other research analysts have also issued reports on the stock. Maxim Group reissued a “hold” rating on shares of Celsion Corporation in a research report on Thursday, June 1st. Zacks Investment Research lowered shares of Celsion Corporation from a “buy” rating to a “hold” rating in a research report on Monday, June 26th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $24.88.

Shares of Celsion Corporation (CLSN) traded down 0.75% during mid-day trading on Friday, reaching $1.33. The company had a trading volume of 31,180 shares. The company’s 50-day moving average price is $1.54 and its 200-day moving average price is $1.09. Celsion Corporation has a 52-week low of $1.24 and a 52-week high of $19.32. The company’s market capitalization is $11.11 million.

TRADEMARK VIOLATION NOTICE: This article was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/09/01/celsion-corporation-clsn-upgraded-to-sell-at-valuengine.html.

A hedge fund recently raised its stake in Celsion Corporation stock. Renaissance Technologies LLC boosted its stake in Celsion Corporation (NASDAQ:CLSN) by 396.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 684,798 shares of the biotechnology company’s stock after buying an additional 546,813 shares during the period. Renaissance Technologies LLC owned 2.63% of Celsion Corporation worth $208,000 as of its most recent SEC filing. Institutional investors and hedge funds own 7.47% of the company’s stock.

About Celsion Corporation

Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).

Receive News & Stock Ratings for Celsion Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion Corporation and related stocks with our FREE daily email newsletter.